StockData
ADC Therapeutics SA logo

ADC Therapeutics SA (ADCT) stock

ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$1.34−0.07 (-4.96%)

Close on Nov 13, 2026Market cap $171.08MP/E –Yield –

ADC Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

ADC Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -95.7%. For fiscal 2025 it was -175.3%, against -222.8% the year before. The highest annual figure on record is -74.9% in fiscal 2022.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-175.3%+47.5
FY2024Dec 31, 2024-222.8%+122.3
FY2023Dec 31, 2023-345.1%−270.3
FY2022Dec 31, 2022-74.9%+603.3
FY2021Dec 31, 2021-678.2%+4299.7
FY2019Dec 31, 2019-4977.9%+5819.9
FY2018Dec 31, 2018-10797.9%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-116.5%+132.9
Q2 FY2026Jun 30, 2026-86.1%+214.6
Q1 FY2026Mar 31, 2026-158.1%+9.5
Q4 FY2025Dec 31, 2025-27.8%+153.9
Q3 FY2025Sep 30, 2025-249.4%−11.2
Q2 FY2025Jun 30, 2025-300.7%−90.8
Q1 FY2025Mar 31, 2025-167.6%+90.6
Q4 FY2024Dec 31, 2024-181.7%+324.7
Q3 FY2024Sep 30, 2024-238.1%+84.3
Q2 FY2024Jun 30, 2024-209.9%+43.8
Q1 FY2024Mar 31, 2024-258.2%+54.5
Q4 FY2023Dec 31, 2023-506.4%−469.9
Q3 FY2023Sep 30, 2023-322.4%−256.1
Q2 FY2023Jun 30, 2023-253.7%+118.6
Q1 FY2023Mar 31, 2023-312.6%−276.8
Q4 FY2022Dec 31, 2022-36.5%+165.6
Q3 FY2022Sep 30, 2022-66.3%+477.9
Q2 FY2022Jun 30, 2022-372.3%+1557.7
Q1 FY2022Mar 31, 2022-35.8%–
Q4 FY2021Dec 31, 2021-202.1%–
Q3 FY2021Sep 30, 2021-544.2%–
Q2 FY2021Jun 30, 2021-1930.0%–

More ADC Therapeutics figures

See a number that looks wrong?